Azenta Partners with PRECEDE Foundation to Enhance Pancreatic Cancer Detection and Treatment

Azenta Partners with PRECEDE Foundation to Combat Pancreatic Cancer

Azenta, Inc. (Nasdaq: AZTA) announces a significant partnership with the PRECEDE Foundation, a leading global consortium focused on the early detection and prevention of pancreatic cancer. This disease ranks as the third-leading cause of cancer-related fatalities in the United States, with over 66,500 new diagnoses each year and a grim five-year survival rate of just 13%. The PRECEDE Foundation aims to drastically improve these statistics by raising the survival rate to 50% over the next decade. By fostering collaboration among more than 60 prominent academic medical centers worldwide, the Foundation leverages a vast cohort of high-risk patients and employs advanced techniques such as longitudinal data analysis and biospecimen tracking to enhance screening and risk modeling.

In this collaboration, Azenta will play a crucial role by providing secure storage solutions for study samples in its biorepository while also managing the logistics necessary for research operations. Kathi Shea, Azenta's Chief Client Solutions Officer, emphasizes the critical importance of early detection in improving survival rates for pancreatic cancer patients. This partnership not only enhances Azenta's involvement in the biorepository sector but also reinforces its reputation as a reliable partner in impactful life sciences research. By allowing PRECEDE researchers to focus on advancing diagnostics and patient outcomes, Azenta supports a mission that seeks to transform the prognosis for individuals at hereditary risk of pancreatic cancer.

The PRECEDE Foundation's dedication to innovation in early detection is a vital component of this partnership. With a collective goal of improving patient care and outcomes, both organizations aim to drive significant advancements in the understanding and treatment of pancreatic cancer. The Foundation is set to host its Annual Meeting this November, where experts will gather to discuss progress and strategies for effective collaboration in the fight against this devastating disease.

In addition to its collaboration with the PRECEDE Foundation, Azenta continues to strengthen its position in the life sciences industry by enhancing its biobanking capabilities. This partnership marks a pivotal step in addressing the urgent need for improved pancreatic cancer diagnostics and treatment options. Azenta's commitment to supporting groundbreaking research initiatives showcases its role in advancing healthcare solutions that have a lasting impact on patient lives. For further details on the PRECEDE Foundation’s mission and initiatives, interested parties are encouraged to visit www.precedefoundation.org.